The Business Intelligence Group selected TraceLink for its ability to integrate autonomous agents into the highly sensitive pharmaceutical environment. In an industry where compliance dictates patient safety, AI cannot operate as a disconnected tool. The OPUS platform ensures that every action taken by an agent regarding serialized product data or partner coordination is recorded, permissioned, and inspection-ready.
In section Releases
TraceLink Named Finalist in 2026 Fortress Cybersecurity Awards
TraceLink has secured a finalist spot in the 2026 Fortress Cybersecurity Awards, earning recognition for its OPUS platform and AI-driven agents. The platform distinguishes itself by bringing regulated pharmaceutical supply chains into a secure, auditable framework where AI agents function with the same level of oversight as human operators.
Performance metrics provided by the company underscore the scale of this operation. TraceLink currently manages over 73 billion serialized pharmaceutical products, maintaining 99.98% system availability. Furthermore, the company boasts a CyberVadis score of 993 out of 1,000, supported by rigorous third-party validations including ISO 27001, SOC 1 Type II, and SOC 2 Type II attestations. By applying GAMP 5-aligned validation to its agents, TraceLink enables life sciences firms to adopt AI without compromising regulatory standards like FDA 21 CFR Part 11.
Comments (0)
No comments yet. Be the first!